SYRA HEALTH CORP - CLASS A (SYRA) Stock Fundamental Analysis
NASDAQ:SYRA - Nasdaq - US87168W2035 - Common Stock - Currency: USD
Overall SYRA gets a fundamental rating of 1 out of 10. We evaluated SYRA against 109 industry peers in the Health Care Providers & Services industry. While SYRA seems to be doing ok healthwise, there are quite some concerns on its profitability. SYRA is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year SYRA has reported negative net income.
In the past year SYRA has reported a negative cash flow from operations.
1.2 Ratios
SYRA has a worse Return On Assets (-96.05%) than 93.52% of its industry peers.
With a Return On Equity value of -127.61%, SYRA is not doing good in the industry: 81.48% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -96.05% | ||
| ROE | -127.61% | ||
| ROIC | N/A |
ROA(3y)-50.35%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
SYRA has a Gross Margin (22.99%) which is in line with its industry peers.
The Profit Margin and Operating Margin are not available for SYRA so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 22.99% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
SYRA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SYRA has more shares outstanding
Compared to 1 year ago, SYRA has an improved debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -1.08, we must say that SYRA is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of SYRA (-1.08) is worse than 80.56% of its industry peers.
SYRA has a Debt/Equity ratio of 0.07. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.07, SYRA is in the better half of the industry, outperforming 75.93% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.07 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.08 |
ROIC/WACCN/A
WACC8.85%
2.3 Liquidity
A Current Ratio of 4.63 indicates that SYRA has no problem at all paying its short term obligations.
SYRA has a Current ratio of 4.63. This is amongst the best in the industry. SYRA outperforms 93.52% of its industry peers.
SYRA has a Quick Ratio of 4.63. This indicates that SYRA is financially healthy and has no problem in meeting its short term obligations.
SYRA has a Quick ratio of 4.63. This is amongst the best in the industry. SYRA outperforms 94.44% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.63 | ||
| Quick Ratio | 4.63 |
3. Growth
3.1 Past
The Earnings Per Share has been growing slightly by 7.00% over the past year.
Looking at the last year, SYRA shows a very negative growth in Revenue. The Revenue has decreased by -17.37% in the last year.
EPS 1Y (TTM)7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%29.29%
Revenue 1Y (TTM)-17.37%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%42.47%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-6%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year33.64%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for SYRA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SYRA. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
SYRA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
SYRA HEALTH CORP - CLASS A
NASDAQ:SYRA (2/13/2025, 4:33:10 PM)
After market: 0.41 -0.03 (-6.82%)0.44
+0.05 (+12.04%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners0.77%
Inst Owner Change-53.25%
Ins Owners0.62%
Ins Owner Change0%
Market Cap4.32M
AnalystsN/A
Price Target1.84 (318.18%)
Short Float %12.72%
Short Ratio0.45
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)31.81%
Min EPS beat(2)-8.36%
Max EPS beat(2)71.99%
EPS beat(4)1
Avg EPS beat(4)-6.05%
Min EPS beat(4)-74.29%
Max EPS beat(4)71.99%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)9.43%
Min Revenue beat(2)7.93%
Max Revenue beat(2)10.93%
Revenue beat(4)3
Avg Revenue beat(4)4.77%
Min Revenue beat(4)-22.31%
Max Revenue beat(4)22.54%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-50%
EPS NQ rev (1m)0%
EPS NQ rev (3m)58.82%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-39.98%
Revenue NY rev (1m)0%
Revenue NY rev (3m)3.4%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.56 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.3 | ||
| P/tB | 1.3 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.65
EYN/A
EPS(NY)-0.54
Fwd EYN/A
FCF(TTM)-0.46
FCFYN/A
OCF(TTM)-0.46
OCFYN/A
SpS0.79
BVpS0.34
TBVpS0.34
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -96.05% | ||
| ROE | -127.61% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 22.99% | ||
| FCFM | N/A |
ROA(3y)-50.35%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover1.75
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.07 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 16.38% | ||
| Cap/Sales | 0.14% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.63 | ||
| Quick Ratio | 4.63 | ||
| Altman-Z | -1.08 |
F-Score4
WACC8.85%
ROIC/WACCN/A
Cap/Depr(3y)1281.02%
Cap/Depr(5y)N/A
Cap/Sales(3y)0.96%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%29.29%
EPS Next Y-6%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-17.37%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%42.47%
Revenue Next Year33.64%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-6.7%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-17.29%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-22.95%
OCF growth 3YN/A
OCF growth 5YN/A